Is Biogen (BIIB) bracing for a fight? What does Jack Daniels have to do with immunotherapy? And will “micro-dosing” light the way to actual therapies?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, we dig into Biogen’s escalating problems with shareholder confidence, looking to the company’s past as a guide to what could be a rocky future. Then, STAT’s Matthew Herper joins us to talk about his story on the early days of cancer immunotherapy, a tale full of happenstance, sliding doors, and a fair amount of whiskey. Finally, STAT’s Meghana Keshavan dials in from the Milken Institute’s Global conference to discuss the rising popularity of psilocybin as a treatment for disease.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy